 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 123» |
- Litfulo (ritlecitinib) / Pfizer, Olumiant (baricitinib) / Eli Lilly, Leqselvi (deuruxolitinib) / Sun Pharma
Medicaid Insurance Coverage for Treatment of Alopecia Areata with Janus Kinase Inhibitors () - Feb 26, 2025 - Abstract #AAD2025AAD_3529;
Dermatologists should also champion policy updates to bridge the large coverage gap for baricitinib between AA and RA treatment. Advocacy efforts are needed to improve Medicaid coverage and ensure equitable access to JAK inhibitors for treating AA.
- Switching between Janus kinase inhibitors for treatment of alopecia areata (Orange County Convention Center (West Building, Exhibit Hall B4, Poster Center 1)) - Feb 26, 2025 - Abstract #AAD2025AAD_3233;
Switching JAKis may benefit patients with severe alopecia areata who fail initial treatment. Whether this is due to dose effect or JAK specificity requires further study.
- Litfulo (ritlecitinib) / Pfizer, Olumiant (baricitinib) / Eli Lilly, Leqselvi (deuruxolitinib) / Sun Pharma
Patient Preferences for the Treatment of Alopecia Areata (Orange County Convention Center (West Building, Exhibit Hall B4, Poster Center 2)) - Feb 21, 2025 - Abstract #AAD2025AAD_2823;
Whether this is due to dose effect or JAK specificity requires further study. This study found that, with regard to JAK-inhibitor treatment options in AA, given similar safety profiles, patients prefer higher efficacy and shorter time to initial hair regrowth, regardless of daily or twice daily dosing.
- Leqselvi (deuruxolitinib) / Sun Pharma
Optimization of deuruxolitinib dosing in adult patients with alopecia areata: Results from a randomized, parallel-group, multicenter, Phase 2 trial () - Feb 21, 2025 - Abstract #AAD2025AAD_2781;
P2
This study found that, with regard to JAK-inhibitor treatment options in AA, given similar safety profiles, patients prefer higher efficacy and shorter time to initial hair regrowth, regardless of daily or twice daily dosing. Hair regrowth was greater with deuruxolitinib 8 mg BID; BID dosing was carried into Phase 3 trials.
- Litfulo (ritlecitinib) / Pfizer, Olumiant (baricitinib) / Eli Lilly, Leqselvi (deuruxolitinib) / Sun Pharma
A Discrete Choice Experiment to Assess Clinician Preferences for the Treatment of Alopecia Areata () - Feb 21, 2025 - Abstract #AAD2025AAD_2777;
Blinded profiles approximating baricitinib 4mg, ritlecitinib, and deuruxolitinib 8mg were ranked as most and least preferred. Our study demonstrated that, regarding JAK-inhibitor treatment of AA, clinicians preferred options with higher efficacy and shorter time to onset, regardless of daily or twice daily dosing.
- Leqselvi (deuruxolitinib) / Sun Pharma
Improvement in anxiety and depression in adult patients with severe alopecia areata treated with deuruxolitinib: Pooled data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials (Orange County Convention Center (West Building, Exhibit Hall B4, Poster Center 2)) - Feb 21, 2025 - Abstract #AAD2025AAD_2627;
P3
Our study demonstrated that, regarding JAK-inhibitor treatment of AA, clinicians preferred options with higher efficacy and shorter time to onset, regardless of daily or twice daily dosing. Deuruxolitinib 8 mg BID was associated with clinically meaningful improvement in the overall HADS, HADS-A, and HADS-D scores from baseline to Week 24 in patients with severe AA.
- Litfulo (ritlecitinib) / Pfizer, Olumiant (baricitinib) / Eli Lilly, Leqselvi (deuruxolitinib) / Sun Pharma
Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score. () - Feb 21, 2025 - Abstract #AAD2025AAD_2577;
Background: For adult patients with severe AA, 3 Janus kinase (JAK) inhibitors are currently approved in the United States: baricitinib (2 mg and 4 mg regimens), ritlecitinib (50 mg regimen), and deuruxolitinib (8 mg regimen). Deuruxolitinib was associated with numerically or statistically greater efficacy when compared to other approved systemic JAK inhibitors for severe AA.
- Leqselvi (deuruxolitinib) / Sun Pharma
Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials () - Feb 21, 2025 - Abstract #AAD2025AAD_2214;
P3
Deuruxolitinib was associated with numerically or statistically greater efficacy when compared to other approved systemic JAK inhibitors for severe AA. More than 95% of patients who achieved clinically meaningful hair regrowth with deuruxolitinib 8 mg BID changed their scalp hair self-assessment from baseline dissatisfaction to satisfaction at W24.
- Leqselvi (deuruxolitinib) / Sun Pharma
Optimization of deuruxolitinib dosing in adult patients with alopecia areata: Results from a randomized, parallel-group, multicenter, Phase 2 trial (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3757;
P2
More than 95% of patients who achieved clinically meaningful hair regrowth with deuruxolitinib 8 mg BID changed their scalp hair self-assessment from baseline dissatisfaction to satisfaction at W24. Deuruxolitinib 8 mg BID resulted in greater improvement relative to deuruxolitinib 16 mg QD, and BID dosing was carried into the Phase 3 trial program.
- Leqselvi (deuruxolitinib) / Sun Pharma
Improvement in anxiety and depression in adult patients with severe alopecia areata treated with deuruxolitinib: Pooled data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3701;
P3
Deuruxolitinib 8 mg BID resulted in greater improvement relative to deuruxolitinib 16 mg QD, and BID dosing was carried into the Phase 3 trial program. A significantly greater proportion of patients treated with deuruxolitinib 8 mg BID vs placebo reported clinically meaningful improvement in overall HADS score, as well as the HADS-A and HADS-D subscales, from baseline to Week 24.
- ||||||| Leqselvi (deuruxolitinib) / Sun Pharma
Trial completion: European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults with Alopecia Areata (clinicaltrials.gov) - Jul 31, 2024
P3, N=407, Completed, Sponsor: Concert Pharmaceuticals
A significantly greater proportion of patients treated with deuruxolitinib 8 mg BID vs placebo reported clinically meaningful improvement in overall HADS score, as well as the HADS-A and HADS-D subscales, from baseline to Week 24. Active, not recruiting --> Completed
- |||| Leqselvi (deuruxolitinib) / Sun Pharma
Trial primary completion date: Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata (clinicaltrials.gov) - Jul 31, 2024
P2/3, N=1000, Active, not recruiting, Sponsor: Concert Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Jan 2025 --> May 2025
- ||| Leqselvi (deuruxolitinib) / Sun Pharma
Clinical, P3 data, Journal: Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1). (Pubmed Central) - Jul 27, 2024
P3
Both doses of deuruxolitinib were effective for hair regrowth. Patient satisfaction aligned with hair growth.
- Leqselvi (deuruxolitinib) / Sun Pharma
Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials (G104-G105) - Jul 18, 2024 - Abstract #EADV2024EADV_1475;
More than 95% of patients who achieved clinically meaningful hair regrowth (SALT score ? 20) during 24 weeks of deuruxolitinib 8 mg BID treatment changed their assessment of their scalp hair from dissatisfaction at baseline to satisfaction at Week 24.
- ||||| Leqselvi (deuruxolitinib) / Sun Pharma
Enrollment closed: Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata (clinicaltrials.gov) - Jul 3, 2024
P2/3, N=1000, Active, not recruiting, Sponsor: Concert Pharmaceuticals
20) during 24 weeks of deuruxolitinib 8 mg BID treatment changed their assessment of their scalp hair from dissatisfaction at baseline to satisfaction at Week 24. Enrolling by invitation --> Active, not recruiting
- || Review, Journal: Novel investigational drugs for alopecia areata and future perspectives. (Pubmed Central) - Jun 7, 2024
The results of landmark phase 3 trials for three JAK inhibitors, baricitinib, ritlecitinib, and deuruxolitinib are discussed...It is uncertain how long patients should remain on JAK inhibitors; discontinuation often leads to relapse. A black-box warning for JAK inhibitors was extrapolated from safety data in a rheumatoid arthritis cohort; recent meta-analyses of JAK inhibitors used in dermatology cohorts do not demonstrate the same risk profile.
- |||| Leqselvi (deuruxolitinib) / Sun Pharma
Trial completion date, Trial primary completion date: Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata (clinicaltrials.gov) - May 31, 2024
P2/3, N=1000, Enrolling by invitation, Sponsor: Concert Pharmaceuticals
A black-box warning for JAK inhibitors was extrapolated from safety data in a rheumatoid arthritis cohort; recent meta-analyses of JAK inhibitors used in dermatology cohorts do not demonstrate the same risk profile. Trial completion date: Sep 2024 --> Feb 2025 | Trial primary completion date: Jun 2024 --> Jan 2025
- deuruxolitinib (CTP-543) / Sun Pharma
Pooled patient-reported outcomes from the phase 3 THRIVE-AA1 and THRIVE-AA2 trials of deuruxolitinib in adult patients with moderate to severe alopecia areata () - Apr 9, 2024 - Abstract #AMCP2024AMCP_386;
- deuruxolitinib (CTP-543) / Sun Pharma
Pooled safety assessments from the multinational phase 3 THRIVE-AA1 and THRIVE-AA2 trials of deuruxolitinib in adult patients with moderate to severe alopecia areata () - Apr 9, 2024 - Abstract #AMCP2024AMCP_385;
- deuruxolitinib (CTP-543) / Sun Pharma
Efficacy of the oral JAK1/JAK2 inhibitor deuruxolitinib in adult patients with moderate to severe alopecia areata: Pooled results from the multinational double-blind, placebo-controlled THRIVE-AA1 and THRIVE-AA2 phase 3 trials () - Apr 9, 2024 - Abstract #AMCP2024AMCP_384;
- |||| Leqselvi (deuruxolitinib) / Sun Pharma
Trial completion date, Trial primary completion date: Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata (clinicaltrials.gov) - Apr 4, 2024
P2/3, N=1000, Enrolling by invitation, Sponsor: Concert Pharmaceuticals
Trial completion date: Sep 2024 --> Feb 2025 | Trial primary completion date: Jun 2024 --> Jan 2025 Trial completion date: May 2024 --> Sep 2024 | Trial primary completion date: Feb 2024 --> Jun 2024
- deuruxolitinib (CTP-543) / Sun Pharma
Deuruxolitinib Demonstrates Significant and Continual Improvement in Scalp Hair Regrowth at 68 Weeks of Dosing in Patients With Alopecia Areata: Pooled Efficacy Results From Ongoing Open-Label Extensi (Room 20B) - Mar 1, 2024 - Abstract #AAD2024AAD_3782;
- deuruxolitinib (CTP-543) / Sun Pharma
Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA2 Trial of Deuruxolitinib in Adult Patients with Alopecia Areata () - Feb 20, 2024 - Abstract #AAD2024AAD_2471;
Patient-reported satisfaction improved significantly at 12 and through 24 weeks with both deuruxolitinib doses vs placebo for eyebrows/eyelashes (all p<0.0001). Conclusion Consistent with THRIVE-AA1, both quantitative measures of eyebrow and eyelash hair growth and patient satisfaction with eyebrows and eyelashes were higher in both deuruxolitinib groups vs placebo.
- deuruxolitinib (CTP-543) / Sun Pharma
Pooled Patient-Reported Outcomes from the Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)) - Feb 20, 2024 - Abstract #AAD2024AAD_2470;
Conclusion Consistent with THRIVE-AA1, both quantitative measures of eyebrow and eyelash hair growth and patient satisfaction with eyebrows and eyelashes were higher in both deuruxolitinib groups vs placebo. Both doses of deuruxolitinib were also significantly different vs placebo at Week 24 on the patient global impression of severity (mean change from baseline
- deuruxolitinib (CTP-543) / Sun Pharma
Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata () - Feb 20, 2024 - Abstract #AAD2024AAD_2469;
Incidence and severity of AEs were similar for the 8mg BID and 12mg BID groups. Discussion Both doses of deuruxolitinib were generally well tolerated, and the overall safety profile in patients with alopecia areata indicates suitability for clinical use.
- deuruxolitinib (CTP-543) / Sun Pharma
Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)) - Feb 20, 2024 - Abstract #AAD2024AAD_2421;
Discussion Both doses of deuruxolitinib resulted in significant regrowth of scalp hair from 8 weeks, continuing throughout 24 weeks. These results demonstrate the clinically meaningful efficacy of deuruxolitinib for moderate to severe AA.
- || Review, Journal: Alopecia areata: What's new in the diagnosis and treatment with JAK inhibitors? (Pubmed Central) - Feb 5, 2024
This review focuses on the evaluation, diagnosis, and treatment of AA. We also provide the latest information on the safety and efficacy of JAK inhibitors for the treatment of AA and describe their mechanisms of action.
- Litfulo (ritlecitinib) / Pfizer, deuruxolitinib (CTP-543) / Sun Pharma
Partial Restoration of Scalp Microbiota in Alopecia Areata with JAK Inhibitors () - Nov 6, 2023 - Abstract #ISDS2023ISDS_249;
In summary, our study sheds light on alterations in scalp microbiota associated with AA and suggests a potential impact of JAK inhibitors on the skin microbiome in the context of AA treatment. These findings contribute to a better understanding of AA's pathophysiology and may have implications for the development of personalized therapeutic approaches targeting the skin microbiota.
- Risk-Benefit Appraisal of Systemic JAK Inhibitors for Alopecia Areata: A Comprehensive Meta-Analysis Assessing Safety and Adverse Effects () - Nov 6, 2023 - Abstract #ISDS2023ISDS_235;
The OR for common side effects, notably URI, showed an above 6-fold increase compared to placebos. Nevertheless, the data underscores a restrained risk for severe adverse events.
- ||| Clinical, Retrospective data, Review, Journal, Adverse events: Janus Kinase Inhibitors and Adverse Events of Acne: A Systematic Review and Meta-Analysis. (Pubmed Central) - Oct 18, 2023
Patients should be properly counseled on this potential adverse effect of these medications before treatment initiation. Future studies are needed to further elucidate the pathophysiology of this association.
- deuruxolitinib (CTP-543) / Sun Pharma
Deuruxolitinib demonstrates significant and continual improvement in scalp hair regrowth at 52 weeks of dosing in patients with alopecia areata: Pooled efficacy results from ongoing open-label extension trials (Hall B) - Sep 27, 2023 - Abstract #EADV2023EADV_4603;
P3
These data demonstrate that a high proportion of patients achieve clinically meaningful improvements in scalp hair regrowth with deuruxolitinib over 52 weeks of dosing. Further analyses in the ongoing OLE trials will detail hair regrowth beyond 52 weeks.
- deuruxolitinib (CTP-543) / Sun Pharma
Improvements in eyebrow and eyelash regrowth with deuruxolitinib (CTP-543) treatment of moderate to severe alopecia areata: Patient- and clinician-reported outcomes from the multinational, double-blind, placebo-controlled THRIVE-AA2 Phase 3 trial (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_3448;
P2, P3
Further analyses in the ongoing OLE trials will detail hair regrowth beyond 52 weeks. Consistent with results from the THRIVE-AA1 trial, both clinician-rated assessments and patient satisfaction with eyebrow and eyelash hair were significantly higher for both deuruxolitinib 8 mg and deuruxolitinib 12 mg vs placebo, starting at 12 weeks and extending through 24 weeks of treatment.
- deuruxolitinib (CTP-543) / Sun Pharma
Patient satisfaction and impressions of severity of moderate to severe alopecia areata are improved by deuruxolitinib (CTP-543): Patient-reported outcomes from the multinational, double-blind, placebo-controlled THRIVE-AA2 Phase 3 trial (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_3447;
P2, P3
Consistent with results from the THRIVE-AA1 trial, both clinician-rated assessments and patient satisfaction with eyebrow and eyelash hair were significantly higher for both deuruxolitinib 8 mg and deuruxolitinib 12 mg vs placebo, starting at 12 weeks and extending through 24 weeks of treatment. Consistent with data from THRIVE-AA1, patient satisfaction and impressions of severity and improvement of scalp hair were significantly higher with both doses of deuruxolitinib vs placebo, demonstrating that significant improvements in patient satisfaction are achieved alongside the efficacy of deuruxolitinib.
- deuruxolitinib (CTP-543) / Sun Pharma
Deuruxolitinib (CTP-543) is generally well tolerated in patients with moderate to severe alopecia areata: Safety results from the multinational, double-blind, placebo-controlled THRIVE-AA2 Phase 3 trial (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_3446;
P2, P3
These results, similar to those obtained in THRIVE-AA1, demonstrate that both doses of deuruxolitinib were generally well tolerated, which reinforces the concept that the overall safety profile when administered to patients with moderate to severe AA is encouraging. These results also demonstrate that deuruxolitinib is consistent with the known safety profiles of other JAK inhibitors.
- deuruxolitinib (CTP-543) / Sun Pharma
Deuruxolitinib (CTP-543) achieves significant regrowth of scalp hair in adult patients with moderate to severe alopecia areata: Efficacy results from the multinational, double-blind, placebo-controlled THRIVE-AA2 Phase 3 trial (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_3445;
P2, P3
Both doses of deuruxolitinib resulted in significant regrowth of scalp hair, starting as early as 12 weeks and continuing throughout the 24-week study period. The results are consistent with data from the THRIVE- AA1 trial, demonstrating the considerable efficacy of deuruxolitinib in the treatment of moderate to severe AA.
- | Dupixent (dupilumab) / Sanofi, Regeneron
Journal, Monotherapy: The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta-analyses of clinical trials. (Pubmed Central) - Jul 15, 2023
The results are consistent with data from the THRIVE- AA1 trial, demonstrating the considerable efficacy of deuruxolitinib in the treatment of moderate to severe AA. Our results support the conduct of high-quality comparative trials to determine whether JAK inhibitors are more effective and safer than PDE4 inhibitors.
- What () - Jul 3, 2023 - Abstract #WCD2023WCD_5896;
There are multiple new treatments on the horizon for AA. Our review focuses on recent clinical trials for this condition and highlights what is to come as far as new and emerging treatments
- Adverse events in patients treated with Jak-inhibitors for alopecia areata: a systematic review () - Jul 3, 2023 - Abstract #WCD2023WCD_5751;
The AEs in AA patients receiving JAK-I are mostly mild and self-limited and predominantly consist of an increased risk of infections and laboratory abnormalities. No fatal outcomes or thromboembolism events have been reported
- ||||| Leqselvi (deuruxolitinib) / Sun Pharma
Enrollment change: European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults with Alopecia Areata (clinicaltrials.gov) - Jun 1, 2023
P3, N=407, Active, not recruiting, Sponsor: Concert Pharmaceuticals
No fatal outcomes or thromboembolism events have been reported N=300 --> 407
- |||| Leqselvi (deuruxolitinib) / Sun Pharma
Trial completion, Trial primary completion date: A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (clinicaltrials.gov) - Jun 1, 2023
P2, N=317, Completed, Sponsor: Concert Pharmaceuticals
N=300 --> 407 Active, not recruiting --> Completed | Trial primary completion date: Jan 2023 --> May 2023
- | Journal: Overview of alopecia areata for managed care and payer stakeholders in the United States. (Pubmed Central) - May 23, 2023
However, several novel therapies that specifically target the immunopathology of AA have emerged, including Janus kinase (JAK) 1/2 inhibitors such as baricitinib and deuruxolitinib, and the JAK3/tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinase inhibitor ritlecitinib...Pezalla is a paid consultant to Pfizer for market access and payer strategy concerns; Fung, Tran, Bourret, Takiya, Peeples-Lamirande, and Napatalung are employees of Pfizer and hold stock in Pfizer. This article was funded by Pfizer.
- || Review: Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review. (Pubmed Central) - May 22, 2023
The OR for upper respiratory tract infections varied from over 7-fold increased to comparable to placebo. The risk of serious adverse events was not increased.
- Olumiant (baricitinib) / Incyte, Eli Lilly, deuruxolitinib (CTP-543) / Sun Pharma
Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis () - Apr 30, 2023 - Abstract #EAACI2023EAACI_654;
However, the response depends on the dosage of the drug. More randomized trials, with identical inclusion criteria and dose and duration of treatment, are required to confirm these findings.
- || Review, Journal: Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors. (Pubmed Central) - Mar 20, 2023
In contrast, PDE-4 inhibitors (apremilast) and the biologics (dupilumab, secukinumab and aldesleukin) appear to have limited efficacy thus far. Results from ongoing and future long-term studies could shed light on the utility of the newer agents in altering the progression of AA.
- deuruxolitinib (CTP-543) / Sun Pharma
Results From Thrive-Aa2: A Double Blind, Placebo-Controlled Phase 3 Clinical Trial Of Deuruxolitinib (Ctp-543), An Oral Jak Inhibitor, In Adult Patients With Moderate To Severe Alopecia Areata (New Orleans Theater B) - Mar 4, 2023 - Abstract #AAD2023AAD_3214;
- |||| Leqselvi (deuruxolitinib) / Sun Pharma
Trial primary completion date: European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults with Alopecia Areata (clinicaltrials.gov) - Mar 1, 2023
P3, N=300, Active, not recruiting, Sponsor: Concert Pharmaceuticals
Results from ongoing and future long-term studies could shed light on the utility of the newer agents in altering the progression of AA. Trial primary completion date: Jun 2023 --> Jun 2024
- |||| Leqselvi (deuruxolitinib) / Sun Pharma
Trial completion date, Trial primary completion date: Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata (clinicaltrials.gov) - Mar 1, 2023
P2/3, N=1000, Enrolling by invitation, Sponsor: Concert Pharmaceuticals
Trial primary completion date: Jun 2023 --> Jun 2024 Trial completion date: May 2023 --> May 2024 | Trial primary completion date: Feb 2023 --> Feb 2024
- || Leqselvi (deuruxolitinib) / Sun Pharma
Trial primary completion date: A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (clinicaltrials.gov) - Feb 1, 2023
P2, N=300, Active, not recruiting, Sponsor: Concert Pharmaceuticals
Trial completion date: May 2023 --> May 2024 | Trial primary completion date: Feb 2023 --> Feb 2024 Trial primary completion date: Oct 2022 --> Jan 2023
- || Olumiant (baricitinib) / Incyte, Eli Lilly, ruxolitinib deuterated (CTP-543) / Concert Pharma
Retrospective data, Review, Journal: Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis. (Pubmed Central) - Jan 26, 2023
However, the response depends on the dosage of the drug. More randomized trials, with identical inclusion criteria and dose and duration of treatment, are required to confirm these findings.
- ||| Leqselvi (deuruxolitinib) / Sun Pharma
Trial completion date: European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults with Alopecia Areata (clinicaltrials.gov) - Dec 27, 2022
P3, N=300, Active, not recruiting, Sponsor: Concert Pharmaceuticals
More randomized trials, with identical inclusion criteria and dose and duration of treatment, are required to confirm these findings. Trial completion date: Jun 2023 --> Jul 2024